Expression and Clinical Significance of ROR1，EGFR and Ki-67 in Lung Adenocarcinoma with Different Histological Types

Zhensong ZHAO; Jinbao XI; Xinyan CHEN; Zihan BAI; Caixin YIN; Huajun ZHAO; Xiaoyu TUO

Article Contents

Article Navigation > Journal of Kunming Medical University > 2026 > Accepted Manuscript

Zhensong ZHAO, Jinbao XI, Xinyan CHEN, Zihan BAI, Caixin YIN, Huajun ZHAO, Xiaoyu TUO. Expression and Clinical Significance of ROR1，EGFR and Ki-67 in Lung Adenocarcinoma with Different Histological Types[J]. Journal of Kunming Medical University.

Citation:

PDF( 1345 KB)

Expression and Clinical Significance of ROR1，EGFR and Ki-67 in Lung Adenocarcinoma with Different Histological Types

1.
The First Affiliated Hospital of Kunming Medical University，Kunming Yunnan 650032
2.
Department of Pathology，Lincang People’s Hospital，Lincang Yunnan 677099
3.
Department of Geriatric Psychiatry，Affiliated Center of Mental Health of Kunming Medical University，Kunming Yunnan 650224
4.
Department of Pathology，The First Affiliated Hospital of Kunming Medical University，Kunming Yunnan 650032，China

Received Date: 2026-01-17

Abstract

Abstract

Objective To investigate the clinical significance of receptor tyrosine kinase-like orphan receptor 1 （ROR1）, epidermal growth factor receptor （EGFR）, and cell proliferation nuclear antigen （Ki-67） expression in invasive pulmonary adenocarcinoma （IPA） of different histological grades, and to explore their value in assisting the pathological grading of IPA. Methods A total of 290 patients with pathologically confirmed IPA admitted to the First Affiliated Hospital of Kunming Medical University from June 2019 to June 2021 were enrolled. Cancer tissue specimens were collected and stained with hematoxylin and eosin （HE）. Histological grading was performed according to the International Association for the Study of Lung Cancer （IASLC） criteria. The expression levels of ROR1, EGFR and Ki-67 were determined by immunohistochemical staining using a semi-quantitative scoring method. Statistical analyses were conducted to evaluate the association of high expression of ROR1, EGFR and Ki-67 with different clinicopathological features and the correlations among these three markers. Results High expression levels of ROR1, EGFR and Ki-67 were observed in poorly differentiated IPA, and significant differences in expression were found among well-differentiated, moderately differentiated, and poorly differentiated groups （P < 0.05）. The expression levels of these markers were not associated with patient sex, age, or smoking history （P > 0.05）, but were significantly correlated with aggressive biological behaviors including tumor diameter, histological morphology, lymph node metastasis, nerve invasion, vascular invasion, and pleural invasion （P < 0.05）. Positive correlations were found between ROR1 and EGFR expression （C = 0.342, P < 0.001） and between ROR1 and Ki-67 expression （C = 0.287, P < 0.001）. Conclusion ROR1 in combination with EGFR and Ki-67 may help determine the differentiation degree and biological characteristics of IPA, providing reference evidence for prognosis assessment and treatment decision-making in patients with pulmonary adenocarcinoma.
- Lung adenocarcinoma,
- ROR1,
- EGFR,
- Ki-67,
- Degree of differentiation.

FullText(HTML)

References(44)

References

[1]	Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53.
[2]	Siegel R L, Giaquinto A N, Jemal A. Cancer statistics, 2024[J]. CA A Cancer J Clin, 2024, 74(1): 12-49.
[3]	滕熠, 张晓丹, 夏昌发, 等. 中国与全球癌症发病、死亡和患病对比及其预测分析: GLOBOCAN 2022数据解读[J]. 中华肿瘤防治杂志, 2024, 31(23): 1413-1420. doi: 10.16073/j.cnki.cjcpt.2024.23.01
[4]	Zhang Y, Vaccarella S, Morgan E, et al. Global variations in lung cancer incidence by histological subtype in 2020: A population-based study[J]. Lancet Oncol, 2023, 24(11): 1206-1218. doi: 10.1016/S1470-2045(23)00444-8
[5]	Charpidou A, Hardavella G, Boutsikou E, et al. Unravelling the diagnostic pathology and molecular biomarkers in lung cancer[J]. Breathe (Sheffield), 2024, 20(2): 230192. doi: 10.1183/20734735.0192-2023
[6]	Sharma J, Zhou F, Moreira L A. Pulmonary Adenocarcinoma Updates: Histology, Cytology, and Grading[J]. Arch Pathol Lab Med, 2025, 149(4): e82-e86.
[7]	刘芮, 商建峰, 朴颖实, 等. TTF-1和p40共表达的非小细胞肺癌5例临床病理分析[J]. 临床与实验病理学杂志, 2025, 41(12): 1600-1605. doi: 10.13315/j.cnki.cjcep.2025.12.011
[8]	任丽丽, 金发光, 刘小北. 早期肺癌检测的研究进展[J/OL]. 中华肺部疾病杂志(电子版), 2018, 11(4): 481-485.
[9]	Schilsky J B, Ni A, Ahn L, et al. Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas[J]. Lung Cancer, 2017, 108: 205-211. doi: 10.1016/j.lungcan.2017.03.015
[10]	Li L, Huang W, Ren X, et al. Unlocking the potential: Advancements and future horizons in ROR1-targeted cancer therapies[J]. Sci China Life Sci, 2024, 67(12): 2603-2616. doi: 10.1007/s11427-024-2685-9
[11]	赵鑫, 丁琳, 陈煜选, 等. ROR蛋白在癌症中的研究进展[J]. 中国细胞生物学学报, 2022, 44(12): 2354-2365. doi: 10.11844/cjcb.2022.12.0014
[12]	Qi Z, Shiyi Z, Huili W, et al. Stable silencing of ROR1 regulates cell cycle, apoptosis, and autophagy in a lung adenocarcinoma cell line[J]. International journal of clinical and experimental pathology, 2020, 13(5): 1108-1120.
[13]	Menck K, Heinrichs S, Baden C, et al. The WNT/ROR pathway in cancer: From signaling to therapeutic intervention[J]. Cells, 2021, 10(1): 142. doi: 10.3390/cells10010142
[14]	余家洋, 王春光. 血管生成抑制剂联合厄洛替尼靶向治疗EGFR突变进展期非小细胞肺癌的疗效和安全性: 一项Meta分析[J]. 肿瘤, 2023, 43(1): 29-41. doi: 10.3781/j.issn.1000-7431.2023.2205-0334
[15]	Cao J F, Zhang X, Xia Q, et al. Insights into curcumin’s anticancer activity in pancreatic ductal adenocarcinoma: Experimental and computational evidence targeting HRAS, CCND1, EGFR and AKT1[J]. Bioorg Chem, 2025, 157: 108264. doi: 10.1016/j.bioorg.2025.108264
[16]	Malarz K, Korzuch J, Mrozek-Wilczkiewicz A, et al. Aminofullerenes as targeted inhibitors of EGFR: From pancreatic cancer inhibitors to Drosophila m. Toxicology[J]. Nanomedicine, 2025, 20(6): 585-601. doi: 10.1080/17435889.2025.2461985
[17]	潘诚, 李志华, 徐文正, 等. 肺腺癌中Ki-67表达与EGFR基因突变的相关性及其在预后中的价值[J]. 安徽医科大学学报, 2022, 57(2): 296-300. doi: 10.19405/j.cnki.issn1000-1492.2022.02.025
[18]	Goyal A V, Shukla S, Acharya S, et al. Correlation of microvessel density with histopathological parameters of carcinoma breast[J]. Indian J Med Res, 2023, 158(4): 417-422. doi: 10.4103/ijmr.ijmr_1588_22
[19]	董懂, 黄意恒, 张亚杰, 等. 《中华医学会肺癌临床诊疗指南(2023版)》解读[J]. 中国胸心血管外科临床杂志, 2023, 30(11): 1533-1538. doi: 10.16781/j.CN31-2187/R.20240697
[20]	李媛, 谢惠康, 武春燕. WHO胸部肿瘤分类(第5版)中肺肿瘤部分解读[J]. 中国癌症杂志, 2021, 31(7): 574-580.
[21]	赵丽楠, 王昆仑, 魏明乔, 等. NLR、LDH、CEA、NSE及CYFRA21-1单独及联合检测对非小细胞肺癌患者预后的预测价值[J]. 贵州医科大学学报, 2023, 48(10): 1232-1237. doi: 10.19367/j.cnki.2096-8388.2023.10.018
[22]	Araghi M, Mannani R, Heidarnejad maleki A, et al. Recent advances in non-small cell lung cancer targeted therapy; an update review[J]. Cancer Cell Int, 2023, 23(1): 162. doi: 10.1186/s12935-023-02990-y
[23]	Lee E, Kazerooni E A. Lung cancer screening[J]. Semin Respir Crit Care Med, 2022, 43(6): 839-850. doi: 10.1055/s-0042-1757885
[24]	Heabah N A E, Darwish S A, Eid A M. Evaluation of the prognostic significance of receptor tyrosine kinase-like orphan receptor 1 (ROR1) in lung carcinoma and its relation to lymphangiogenesis and epithelial mesenchymal transition[J]. Pathol Res Pract, 2023, 248: 154703. doi: 10.1016/j.prp.2023.154703
[25]	Raso M G, Barrientos Toro E, Evans K, et al. Heterogeneous profile of ROR1 protein expression across tumor types[J]. Cancers, 2024, 16(10): 1874. doi: 10.3390/cancers16101874
[26]	Tigu A B, Munteanu R, Moldovan C, et al. Therapeutic advances in the targeting of ROR1 in hematological cancers[J]. Cell Death Discov, 2024, 10(1): 471. doi: 10.1038/s41420-024-02239-1
[27]	Liu D L, Gunther K, Enriquez A L, et al. ROR1 is upregulated in endometrial cancer and represents a novel therapeutic target[J]. Scientific reports, 2020, 10(1): 13906-13906. doi: 10.1038/s41598-020-70924-z
[28]	Li Y, Sun H, Bai C, et al. Dihydroartemisinin inhibits tumor progress via blocking ROR1-induced STAT3-activation in non-small cell lung cancer[J]. Int Immunopharmacol, 2024, 133: 112157. doi: 10.1016/j.intimp.2024.112157
[29]	Fukuda T, Chen L, Endo T, et al. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a[J]. Proc Natl Acad Sci U S A, 2008, 105(8): 3047-3052. doi: 10.1073/pnas.0712148105
[30]	Witze E S, Litman E S, Argast G M, et al. Wnt5a control of cell polarity and directional movement by polarized redistribution of adhesion receptors[J]. Science, 2008, 320(5874): 365-369. doi: 10.1126/science.1151250
[31]	Nieto M A, Huang R Y, Jackson R A, et al. Emt: 2016[J]. Cell, 2016, 166(1): 21-45. doi: 10.1016/j.cell.2016.06.028
[32]	陈思宇, 王毅刚. 新型受体酪氨酸激酶ROR1及其靶向肿瘤治疗的研究进展[J]. 中国细胞生物学学报, 2025, 47(1): 111-122.
[33]	王作刚, 冯彦, 于亮, 等. ROR1对人肺癌A549细胞上皮-间质转化的影响[J]. 肿瘤防治研究, 2018, 45(7): 458-462.
[34]	Lopez-Bergami P, Barbero G. The emerging role of Wnt5a in the promotion of a pro-inflammatory and immunosuppressive tumor microenvironment[J]. Cancer Metastasis Rev, 2020, 39(3): 933-952. doi: 10.1007/s10555-020-09878-7
[35]	杨燕君, 董跃华, 张晓丽, 等. 血清CEA与癌组织标本中TTF-1检测对肺腺癌EGFR突变的预测价值[J]. 现代肿瘤医学, 2020, 28(11): 1870-1873. doi: 10.3969/j.issn.1672-4992.2020.11.013
[36]	管旭辉, 林晓程, 杨衿记. EGFR-TKIs 一线治疗EGFR复合突变非小细胞肺癌的疗效及耐药分析[J]. 陆军军医大学学报, 2022, 44(24): 2486-2492.
[37]	赵景景, 谭于飞, 李玲, 等. 吉非替尼对老年晚期EGFR突变型非小细胞肺癌的疗效及对MMP-9、TIMP-1水平的影响[J]. 实用癌症杂志, 2023, 38(1): 156-159. doi: 10.3969/j.issn.1001-5930.2023.01.045
[38]	姬巧霞, 张红斌, 王愿, 等. 晚期非小细胞肺癌患者表皮生长因子受体基因突变的危险因素及表皮生长因子受体酪氨酸激酶抑制剂的疗效分析[J]. 中国医药, 2023, 18(2): 211-215. doi: 10.3760/j.issn.1673-4777.2023.02.012
[39]	刘爽, 刘艳梅, 曲佳哲. 吉非替尼联合化疗方案对EGFR突变晚期非小细胞肺癌患者疗效及CA19-9、CYFRA21-1、CEA表达的影响[J]. 中国实用医药, 2023, 18(3): 106-108. doi: 10.14163/j.cnki.11-5547/r.2023.03.031
[40]	李俏然, 赵信喜, 张新阁, 等. 表皮生长因子受体在非小细胞肺癌中的表达及与患者临床特征的关系[J]. 癌症进展, 2024, 22(12): 1357-1359, 1379. doi: 10.11877/j.issn.1672-1535.2024.22.12.19
[41]	Yamaguchi T, Yanagisawa K, Sugiyama R, et al. NKX2-1/TITF1/TTF-1-induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma[J]. Cancer Cell, 2012, 21(3): 348-361. doi: 10.1016/j.ccr.2012.02.008
[42]	Pan W, Zhang C, Chen M, et al. Expression of Ki-67 and P16 are related with HPV in squamous cell carcinoma of the external auditory canal[J]. J Otolaryngol Head Neck Surg, 2022, 51: 40. doi: 10.1186/s40463-022-00592-8
[43]	刘晓明, 张蓓, 赵丽娜, 等. 乳腺黏液癌患者超声图像特征与PR、ER、HER-2、ER、Ki-67的相关性[J]. 贵州医科大学学报, 2023, 48(11): 1392-1398. doi: 10.19367/j.cnki.2096-8388.2023.11.018
[44]	谢玲. ROR1在三阴性乳腺癌中的表达及其预后意义[D]. 延安: 延安大学, 2020.

Relative Articles(20)

Relative Articles

[1]	Haijun LOU, Zhenyu ZHANG, Alimujiang SUREYAN, Menggen MENG, Hang CHEN, Muli WUDU. Expression Characteristics and Clinical Pathological Features of TMEM33 in Lung Adenocarcinoma. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20250304
[2]	Hongxiu YANG, Zhongshan ZHU. Effect of HPRT1 Gene Expression on Overall Survival of Patients with Lung Adenocarcinoma. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20240803
[3]	Wangxun SHEN, Yinyu YANG, Canwei LI, Jinrong YANG, Sijing WU, Huajun ZHAO, Xiaoyu TUO. Expression and Clinical Significance of ROR1 in Different Histologic Types of Invasive Lung Adenocarcinoma. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20240509
[4]	Fei SONG, Jiayin CHE, Ming HUANG, Dan XU, Hongyang LI, Dingkun LI, Yingying XIANG. The Role of Radioactive Iodine-125 Particles in EMT and Clinical Treatment of Lung Adenocarcinoma. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20230101
[5]	Shiqi MA, Yi DING, Min LI, Mengci WANG, Siyu ZHANG, Shumei FENG. LINC00341 Inhibits the Proliferation of Lung Adenocarcinoma Cells Through the MAPK Pathway. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20230403
[6]	Bangqing LIU, Jianfeng LI, Xiaohui LIU, Jinnan ZHANG, Jinping LIANG. MiR-196b Promotes Proliferation and Migration of Lung Adenocarcinoma by Targeting ERG. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20231023
[7]	Jiang WU, He MA, Jinyun JIANG, Na LIU, Ruihuan ZHAO, Yuefeng HE. The Relationship between Arsenic Exposure and DNA Damage of EGFR，PTEN，Kras，and PIK3CA Genes in Arsenic Factory Workers. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20230717
[8]	Zhongshan ZHU, Zhou YANG, Chengchuan JIANG, Xiaobing LI, Dou REN, Cheng HUANG, Weiwei ZHANG, Xiangjun LI, Shunli ZHAO. An Analysis of PLA2G1B Expression and Prognosis in Patients with Lung Adenocarcinoma. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20220912
[9]	Maofang WU, Yongchun ZHOU, Jingjing CAI, Xin MO, Yinwei LI, Jiahui MAO. EGFR Gene Mutation State and Its Clinical Significance in Multi-nodular Lung Adenocarcinoma in Yunnan Province. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20220215
[10]	Huajun ZHAO, Guoqing PAN, Ying TANG, Zhiyuan WANG, Xiaowei ZHAO, Xiaoyu TUO. Expressions of ROR1 in Lung Adenocarcinoma and Its Relationship with Spread Through Air Apace. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20221128
[11]	Hong-min DUAN, Nan CHEN, Yong-yan YANG, Yun-xia LI, Jin-xiang FENG, Hang LI, Xiu-wen HUANG, Dong-jin LV, Ming ZHANG, Yu-tao ZHAO. Effects and Mechanism of Anlotinib on Radiosensitivity of Non-small Cell Lung Cancer Cell Lines A549. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20210808
[12]	Yan-fen MA, Jian HU, Ning ZHANG, Qian WU, Xiao-qin WANG. Changes and Abnormal Patterns of Coagulation Indicators in Patients with Lung Adenocarcinoma and Tuberculosis Pleural Effusion. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20211021
[13]	Lu YAO, Hui TAN, Yong-hua RUAN, Zhong-yi QIAN, Zhi-hong YANG, Rui RUAN, Qi-ying ZHANG, Ming-ting ZHOU, Xing-yin FANG. Application Value of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration in Diagnosis of Space-occupying Lesions of Lung and Mediastinum. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20210311
[14]	Ying-xia WANG, Qin HE, Guo-fang WANG, Xuan ZHANG. Expression and Significance of microRNA-21 and EGFR in Non-small Cell Lung Cancer. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20210818
[15]	Wu Qi Yan , Bian Ge Yuan , Cheng Hui Jun, Li Jiao Xia , Wang Shu Ting , Huang Zhao Lue . . Journal of Kunming Medical University,
[16]	Zhu Zhong Shan , Yan Wen Hui , Li Xiao Bing , Yang Zhou , Bai Peng . Driver Genes Mutation and Survival Analysis in 200 Patients with Pulmonary Adenocarcinoma Brain Metastasis. Journal of Kunming Medical University,
[17]	Wang Hua . . Journal of Kunming Medical University,
[18]	Zhao Chun Fang . . Journal of Kunming Medical University,
[19]	. The Expressions and Significance of ADAM10,EGFR and E-cadherin in Hepatocellular Carcinoma. Journal of Kunming Medical University,
[20]	. Clinical Research of the Expression and Correlation of KI-67 and Survivin in Cervical Carcinoma. Journal of Kunming Medical University,